The laborious process of naming a pharmaceutical takes months and sometimes years of brainstorming, trademark review, legal ...
Wanted: a cheap, multipotent treatment for viral infections. Must be able to handle new or unfamiliar strains, or (even ...
By Michael Erman NEW YORK, April 27 (Reuters) - Johnson & Johnson is using artificial intelligence to slash by half the time ...
SHANGHAI, SHANGHAI, CHINA, April 30, 2026 /EINPresswire.com/ -- In today’s life sciences industry, moving a drug ...
Accelerated drug development expertise. For small startups and academic spinoffs bringing their first molecules to market, ...
Hosted on MSN
MindRank in phase 3 trial with China’s first AI-assisted new drug, cutting R&D costs by 60%
The company was aiming for approval in the second half of 2028, paving the way for a market launch in 2029 Hangzhou-based biotech start-up MindRank has progressed to Phase 3 clinical trials for its ...
Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug ...
US drug pricing policy and Congressional Budget Office (CBO) model of the Build Back Better Act examining pharmaceutical R&D ...
When we treat cancer patients, their disease can overcome treatment through its innate capacity to adapt. This is at the ...
SAN FRANCISCO, Jan 26 (Reuters) - Artificial intelligence has yet to deliver on the most challenging aspect of drug development -- finding new molecules that lead to major medical advances -- but it ...
Regulatory approval is a major milestone in the drug development process, but it is not the final chapter in the journey.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results